Recent Quotes (30 days)
You have no recent quotes
| ARGS | 6.32 | +0.0200.32% |  |
| AKBA | 8.83 | +0.1401.61% | |
| VNRX | 3.26 | -0.120-3.55% | |
| RWLK | 6.91 | +0.1101.62% | |
| BNTC | 1.24 | -0.068-5.22% | |
| OCUL | 5.51 | -0.255-4.43% | |
| PTX | 0.550 | -0.055-9.06% | |
| NEO | 9.16 | +0.2402.69% | |
| HSGX | 1.98 | -0.030-1.49% | |
| EVOK | 10.26 | +0.6406.65% | |
| STXS | 1.18 | -0.082-6.50% | |
| EBIO | 2.51 | -0.014-0.55% | |
| ECTE | 1.48 | 0.000.00% | |
| AMGN | 162.05 | +1.871.17% | |
| GILD | 86.70 | +0.4500.52% | |
| JNJ | 122.98 | +0.1200.10% | |
| CDXS | 4.27 | +0.1202.89% | |
| MNOV | 7.22 | -0.050-0.69% | |
| FOLD | 5.92 | +0.0100.17% | |
| SGNT | 21.63 | -0.020-0.09% | |
34.16
-0.33
(-0.96%)
Real-time:
3:21PM EDT
NYSE
real-time data -
Disclaimer
Currency in USD
| Range | 33.96 - 34.99 |
| 52 week | 19.74 - 111.22 |
| Open | 34.99 |
| Vol / Avg. | 306,600.00/659,048.00 |
| Mkt cap | 1.10B |
| P/E | - |
| Div/yield | - |
| EPS | -7.97 |
| Shares | 32.49M |
| Beta | -0.14 |
| Inst. own | 95% |
Events
Aug 8, 2016
Q2 2016 Puma Biotechnology Inc Earnings Release (Estimated)
- 4:00PM EDT -
Jun 13, 2016
Puma Biotechnology Inc Annual Shareholders Meeting
Jun 8, 2016
Puma Biotechnology Inc Annual Shareholders Meeting (Estimated)
May 24, 2016
Puma Biotechnology Inc at UBS Global Healthcare Conference
May 11, 2016
Puma Biotechnology Inc at Bank of America Merrill Lynch Health Care Conference -
May 10, 2016
Q1 2016 Puma Biotechnology Inc Earnings Release
|
More events from DailyFinance »
|
Key stats and ratios
| Q1 (Mar '16) | 2015 | |
| Net profit margin | - | - |
| Operating margin | - | - |
| EBITD margin | - | - |
| Return on average assets | -127.94% | -118.87% |
| Return on average equity | -153.48% | -148.14% |
| Employees | 156 | - |
| CDP Score | - | - |
Address
10880 Wilshire Blvd Ste 2150
LOS ANGELES, CA 90024-4106
United States - Map
+1-424-2486500 (Phone)
+1-424-2486501 (Fax)
LOS ANGELES, CA 90024-4106
United States - Map
+1-424-2486500 (Phone)
+1-424-2486501 (Fax)
Website links
External links
Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Research Reports - Reuters
Volume delayed by 15 mins.
Prices are not from all markets.
Sources include SIX.
Prices are not from all markets.
Sources include SIX.
Advertisement
Description
Puma Biotechnology, Inc. is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the global development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), which the Company is developing for the treatment of patients with human epidermal growth factor receptor type 2 (HER2), positive breast cancer, and patients with non-small cell lung cancer, breast cancer and other solid tumors that have a HER2 mutation; PB272 (neratinib (intravenous)), which the Company is developing for the treatment of patients with advanced cancer, and PB357, which is an orally administered agent. Neratinib is a potent irreversible tyrosine kinase inhibitor (TKI) that blocks signal transduction through the epidermal growth factor receptors (EGFRs), HER1, HER2 and HER4.
Officers and directors
| Alan H. Auerbach | Chairman of the Board, President, Chief Executive Officer | |
| Charles R. Eyler | Senior Vice President - Finance and Administration, Treasurer | |
| Richard P. Bryce | Senior Vice President - Clinical Research and Development. | |
| Jay M. Moyes | Director | |
| Adrian M. Senderowicz M.D. | Director | |
| Troy E. Wilson Ph.D., J.D. | Director |